Drug development costs are immense, pushing $2.7 billion on average to get a drug through the development, trial, and approval processes, and finally to market. That isn’t stopping dozens of pharmaceutical companies from working on potential blockbuster treatments like the following three.
Biktarvy – HIV treatment Biktarvy was approved in February and is expected to generate sales of over $2 billion in 2019. The once-a-day treatment is a combination of three different drugs and was found to be generally safe in trials.
Sublocade – Approved towards the end of 2017, Sublocade is an important new treatment in the growing battle against opioid addiction. Despite a slow start, Sublocade is anticipated to top $1 billion in sales by 2022.
Epidiolex – Epileptic seizure treatment Epidiolex became the first FDA-approved drug to use a substance derived from marijuana when it was approved in June. Sales are projected to surpass $1 billion by 2022.